NASDAQ:PDSB PDS Biotechnology Q1 2026 Earnings Report $1.06 +0.01 (+0.47%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast PDS Biotechnology EPS ResultsActual EPSN/AConsensus EPS -$0.15Beat/MissN/AOne Year Ago EPSN/APDS Biotechnology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APDS Biotechnology Announcement DetailsQuarterQ1 2026Date5/13/2026TimeBefore Market OpensConference Call DateWednesday, May 13, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile PDS Biotechnology Earnings HeadlinesPDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial ResultsMay 6 at 8:00 AM | globenewswire.comPDS Biotechnology (NASDAQ:PDSB) and Immunome (NASDAQ:IMNM) Head-To-Head ContrastMay 1, 2026 | americanbankingnews.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 6 at 1:00 AM | Profits Run (Ad)PDS Biotechnology Corp.April 22, 2026 | barrons.comB. Riley Securities Sticks to Their Buy Rating for PDS Biotechnology (PDSB)April 17, 2026 | theglobeandmail.comPDSB stock hits 37-week high — here’s the latest on its therapy to treat metastatic colorectal cancerApril 15, 2026 | msn.comSee More PDS Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PDS Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PDS Biotechnology and other key companies, straight to your email. Email Address About PDS BiotechnologyPDS Biotechnology (NASDAQ:PDSB) Group, Inc. is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials. Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform. The company’s research initiatives include both off‐the‐shelf vaccines targeting shared tumor antigens and personalized approaches that present patient‐specific neoantigens. By integrating novel adjuvant technology with established cancer targets, PDS Biotechnology aims to generate durable T-cell responses and improve clinical outcomes in multiple solid tumor indications. Founded in 2007 and headquartered in San Diego, California, PDS Biotechnology conducts its research, translational studies, and early clinical development across facilities in the United States. The company partners with academic centers and biopharmaceutical organizations to advance its product candidates through global clinical trials. Under the leadership of CEO Bruce D. Montgomery and an experienced management team, PDS Biotechnology is dedicated to translating its platform innovations into next-generation immunotherapies for patients with cancer and chronic viral infections.View PDS Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageYears in the Making, AMD’s Upside Movement Has Just BegunWestern Digital: The Storage Behemoth Skyrocketing on AI DemandOld Money, New Tech: Western Union's Crypto RebootPinterest Pins a Profit Play To Its Mood BoardJust How Big a Problem Could Amazon’s Cash Burn Rate Be?BlackBerry Rewrites Its Own Operating System Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)argenex (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
